Third quarter 2020 results

Sanofi Q3 2020 business EPS growth of 8.8% at CER

Third quarter 2020 results were reviewed by management during a conference call with the financial community.

Presentation
Press release
Q3 2020 income statements
Q3 2020 net sales by GBU, franchise, geographic region and product
R&D appendices
Clinical trials appendices
Download infographic
Q3 2020 Memorandum for modelling purposes

Webcast details

Access the recorded audio webcast

Q3 2020 Results from Sanofi

We achieved strong growth in our treatment for type 2 inflammation disorders and vaccines during Q3. We helped transform the lives of thousands of patients and reduced the spread of vaccine-preventable diseases, even as we continue to fight COVID-19.

Paul Hudson
Chief Executive Officer

Third quarter 2020 results

Sanofi Q3 2020 business EPS growth of 8.8% at CER

Webcast details

Q3 2020 infographic

Paul Hudson comments on Q3 2020 results

Third quarter 2020 results

Third quarter 2020 results

Sanofi Q3 2020 business EPS growth of 8.8% at CER

Webcast details

Q3 2020 infographic

Paul Hudson comments on Q3 2020 results

Follow us